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Abstract. In addition to intracellular calcium, which activates
myosin light chain (MLC) kinase, MLC phosphorylation and
hence contraction is importantly regulated by MLC phosphatase
(MLCP). Recent evidence suggests that distinct signaling cas-
cades of vasoactive hormones interact with the Rho/Rho kinase
(ROK) pathway, affecting the activity of MLCP. The present
study measured the impact of ROK inhibition on vascular F-actin
distribution and on vasoconstriction induced by activation/inhibi-
tion of distinct signaling pathways in vivo in the microcirculation
of the split hydronephrotic rat kidney. Local application of the
ROK inhibitors Y-27632 or HA-1077 induced marked dilation of
pre- and postglomerular vessels. Activation of phospholipase C
with the endothelin ETB agonist IRL 1620, inhibition of soluble
guanylyl cyclase with 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-
one (ODQ), or inhibition of adenylyl cyclase with the adenosine
A1 agonist N6-cyclopentyladenosine (CPA) reduced glomerular
blood flow (GBF) by about 50% through vasoconstriction at
different vascular levels. ROK inhibition with Y-27632 or HA-
1077, but not protein kinase C inhibition with Ro 31-8220,
blunted ETB-induced vasoconstriction. Furthermore, the reduction
of GBF and of vascular diameters in response to ODQ or CPA
were abolished by pretreatment with Y-27632. ROK inhibitors
prevented constriction of preglomerular vessels and of efferent
arterioles with equal effectiveness. Confocal microscopy demon-
strated that Y-27632 did not change F-actin content and distribu-
tion in renal vessels. The results suggest that ROK inhibition
might be considered as a potent treatment of renal vasoconstric-
tion, because it interferes with constriction induced by distinct
signaling pathways in renal vessels without affecting F-actin
structure. alessandro.cavarape@dpmsc.uniud.it
The primary signal for vascular smooth muscle cell (VSMC)
contraction is an increase of intracellular calcium (Ca2) lev-
els, activating myosin light chain (MLC) kinase, which leads to
MLC phosphorylation (1). In the past few years, evidence has
accumulated that enhancement of Ca2 sensitivity of VSMC,
involving inhibition of MLC phosphatase (MLCP), contributes
to VSMC contraction importantly (2). So far, two molecular
mechanisms of MLCP inhibition have been uncovered (3).
First, receptor-mediated activation of the small G protein
RhoA leads to activation of Rho kinase (ROK), which inhibits
MLCP through phosphorylation of its regulatory subunit either
directly or via ZIP-like kinase (4,5). Second, protein kinase C
 and  isoforms have been identified to phosphorylate CPI-
17, which, in the phosphorylated state, inhibits MLCP specif-
ically (6,7). A recently developed ROK inhibitor, the pyridine
derivative Y-27632, has been shown to potently inhibit the
contraction of preparations from experimental animals and
human arterial vessels induced by different agonists in vitro
and also to correct arterial pressure to normotensive levels in
different experimental models of hypertension in vivo (8–11).
Because of the evidence that the Rho/ROK pathway mediates
tonic vasoconstriction, ROK is thought to play a crucial role in
human diseases, e.g., in hypertension and myocardial ischemia
(12,13). The contribution of the ROK pathway to renal vaso-
constriction is practically unknown.
A number of investigations have elucidated the role of a
wide variety of circulating and locally produced vasoactive
molecules in regulating renal hemodynamics under normal and
pathologic conditions (14). Vasoconstrictors bind to specific
receptors to activate intracellular pathways triggering contrac-
tion of VSMC. Also in the kidney, VSMC tone is regulated by
a complex network of constricting and dilating intracellular
signaling cascades, some of which might modulate vasomotor
tone in part independent of changes in intracellular Ca2. Thus,
renal vasoconstrictors could increase Ca2 sensitivity through
MLCP inactivation mediated by ROK. Conversely, VSMC
relaxation mediated by an increase in intracellular cAMP and
cGMP is associated with a decrease of Ca2 sensitivity (3,15).
Evidence has accumulated that cGMP- and cAMP-dependent
protein kinases can directly increase the activity of MLCP and
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interfere with the Rho/ROK pathway (3). However, the role of
ROK in renal vasoconstriction mediated by distinct signaling
pathways has not yet been investigated.
In addition to smooth muscle contraction, the Rho/ROK
pathway stimulates stress fiber formation and actin polymer-
ization in cultured cells (16). Accordingly, ROK inhibition
with Y-27632 completely abolished stress fibers in cultured
cells (11). Though actin filament disruption has been demon-
strated to severely impair vasoconstriction in isolated mesen-
teric arteries (17), F-actin distribution in vessels has not yet
been examined after ROK inhibition.
The aim of this study was to assess the influence of ROK on
renal vasoconstriction at the microvascular level utilizing the in
vivo model of the split hydronephrotic rat kidney. We em-
ployed different approaches to induce vasoconstriction through
distinct intracellular pathways, namely phospholipase C acti-
vation, and reduction of intracellular cGMP or cAMP levels.
Drug-induced constrictions in different renal vascular seg-
ments and reductions in glomerular blood flow (GBF) were
measured under control conditions and after local application
of the ROK inhibitors Y-27632 and HA-1077 as compared
with PKC inhibition. Moreover, we also investigated the effect
of ROK inhibition on actin filament organization in the renal
vascular wall.
Materials and Methods
Preparation of the Hydronephrotic Kidney
The study protocols were performed on 29 female Wistar rats (210
to 240 g) in accordance with national animal protection guidelines.
The animals had free access to food and water before the experiments.
The technique and experimental procedures have been previously
described in detail (18). Briefly, unilateral surgical hydronephrosis
was induced by permanently ligating the left ureter via a flank incision
during pentobarbital sodium anesthesia (Nembutal, 60 mg/Kg intra-
peritoneally; Ceva, Bad Segeberg, Germany). The final experiments
were performed under thiobutabarbital anesthesia (Inactin, 100 mg/kg
intraperitoneally; Byk Gulden, Konstanz, Germany) 2 to 3 mo after
induction of hydronephrosis. Each rat was placed on a 37°C heated
surgical table. The trachea was intubated, and the left jugular vein was
cannulated for the continuous replacement of isotonic saline at a rate
of 60 l/min and for infusion of drugs. A polyethylene catheter was
inserted into the left femoral artery for continuous measurements of
systemic BP. The left hydronephrotic kidney was exposed through a
flank incision and split carefully along the great curvature using a
thermal cautery. The dorsal half of the split kidney was sutured to a
semicircular-shaped wire frame. Blood supply and innervation re-
mained intact after this preparation. The wire frame with the fixed
split kidney was placed at the bottom of a specially designed Plexiglas
chamber suitable for intravital transillumination microscopy. The
entry of the renal hilus into the chamber was sealed with silicon
grease, and the chamber was filled with 50 ml of an isotonic, isocol-
loidal solution (Hemaccel; Behringwerke AG, Marburg, Germany)
maintained at a constant temperature of 37°C with a feedback-con-
trolled heating system.
Videomicroscopy
The table was mounted on the microscope stage. Images of renal
microvessels obtained through a special water-immersion objective
(Ultropak UO-55; Leitz, Wetzlar, Germany) were visualized with a
CCD camera, displayed on a calibrated monitor by a closed circuit TV
system, and recorded on line on videotape. The luminal vessel diam-
eters were measured directly from the monitor and were converted to
in vivo diameters (expressed in micrometers) using a conversion
factor to account for the magnification of the vessel images.
Vessel Segments and GBF
Measurements of the following vessel segments were carried out
according to their branching pattern from the selected glomerulus: (1)
proximal interlobular artery (near the arcuate artery); (2) distal inter-
lobular artery (near the afferent arteriole); (3) proximal afferent arte-
riole (near the interlobular artery); (4) distal afferent arteriole (at a site
within 100 m from the glomerulus); and (5) efferent arteriole (within
50 m from the glomerulus).
Velocity of red blood cells was measured in the efferent arteriole of
the selected glomerulus by using a velocity-tracking correlator (Model
102B; IPM Inc., San Diego, CA). In this on-line computing system
two photodiodes obtain photometric signals from the moving red
blood cells (19). To obtain the GBF value, the measured red cell
velocity was multiplied by the luminal cross-section of the efferent
arteriole and corrected for the Fahreus-Lindqvist effect (20).
Experimental Protocols
After the surgical procedure, each kidney was allowed to adapt to
the tissue bath conditions for at least 60 min. The stability of the
preparation has been demonstrated for a duration of 3 h (21). Each
protocol included several experimental periods at the end of which
mean arterial pressure (MAP), vascular diameters, and GBF were
measured. The first period served as baseline control.
Six series of experiments were performed. In the first series,
dose-response experiments for Y-27632 were conducted. The other
five experimental series started with control measurements during
which the ETB receptor agonist IRL 1620 (group 1, n  6; group 2,
n  5; group 3, n  5), the guanylyl cyclase inhibitor ODQ (group 4,
n 6) or the selective A1 adenosine receptor agonist N6-cyclopenthy-
ladenosine (CPA) (group 5, n  7) were locally administered into the
tissue bath to reduce GBF from a threshold value to about 50% by up
to three sequentially increasing doses of vasoconstrictors. After wash
out (30 min) and baseline measurements in the five experimental
series, measurements were taken after intrarenal inhibition of ROK by
local administration of the selective inhibitors Y-27632 or HA-1077
or after intrarenal inhibition of PKC by local administration of Ro
31–8220. After control measurements, during which the renovascular
parameters were evaluated in a new baseline condition at the steady
state, the effects of IRL 1620, ODQ, and CPA were assessed after
intrarenal inhibition of ROK or PKC, whereby the doses of IRL 1620
and CPA were augmented in groups 1, 4, and 5 to obtain a reduction
in GBF comparable to that detected during the pre-inhibition mea-
surements. Measurements were taken about 10 min after application
of IRL 1620 and CPA and about 15 min after application of ODQ,
Y-27632, HA-1077, and Ro 31–8220, when a steady state had been
reached.
For stimulation of PLC, the ETB agonist IRL 1620 was chosen,
because we have demonstrated earlier that IRL 1620 induces not only
preglomerular vasoconstriction but also marked efferent arteriolar
constriction (22). The effects of IRL 1620 and of A1 receptor agonists
have been shown to be fully reversible after washout (22–24). Fur-
thermore, vasoconstrictions induced by IRL 1620 and A1 receptor
agonists do not desensitize in the hydronephrotic kidney, as is the case
for angiotensin II and diadenosine polyphosphates (22–26). The re-
versibility of the ODQ-induced vasoconstriction was confirmed by
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wash out. To exclude that the renal vasculature desensitized in re-
sponse to ODQ, the protocol was reversed (Y-27632  ODQ, wash-
out, ODQ) in half of the experiments. We obtained similar results for
ODQ with the normal and the reversed protocol; therefore, data were
pooled together.
Y-27632 and HA-1077 have been reported to inhibit ROK with
IC50 values of 8 · 107 M and 2 · 106 M, respectively (27).
Concentrations of 105 M Y-27632 and 2 · 105 M HA-1077 inhibit
PKC by 2% and 14%, respectively (27). The IC50 value of Ro
31–8220 for PKC inhibition is 3 · 108 M, whereas 1 M Ro
31–8220 reduces ROK activity by only 8% (27).
It should be noted that the concentrations of vasoactive drugs,
which are locally administered into the tissue bath, need to be about
tenfold higher to elicit similar effects in the hydronephrotic kidney as
compared with isolated or perfused preparations. For example, 109
M ET-1 and 108 M angiotensin II in the tissue bath constrict afferent
arterioles by about 15%, whereas a similar diameter reduction is seen
with 1010 M ET-1 and 109 M angiotensin II in isolated rat
afferent arterioles (28) or in isolated perfused hydronephrotic kidneys
(29,30). There is most likely a steep concentration gradient for locally
applied drugs between the tissue bath and the vessel lumen, because
the hydronephrotic kidney has a considerable thickness (200 to 400
m) and the concentration of drugs in the blood stream is practically
zero.
IRL 1620 (Alexis, Germany), CPA (Boehringer Mannheim, Ger-
many), Y-27632 (kindly provided by Yoshitomi Pharmaceutical Inc.),
and HA-1077 (Alexis, Germany) were dissolved in saline. ODQ and
Ro 31–8220 (Alexis, Germany) were dissolved in DMSO; the final
DMSO concentration in the tissue bath was below 0.1%. All the
vasoactive drugs used in our experiments were administered into the
tissue bath by local application to avoid any systemic effect on
hemodynamic parameters.
Examination of F-Actin Distribution
Hydronephrotic kidneys were prepared for videomicroscopy as
described above. Hydronephrotic kidneys were incubated with either
vehicle (controls) or 104 M Y-27632 for 30 min. Hydronephrotic
kidneys were then excised and fixed in 2% paraformaldehyde for
2.5 h. The kidney tissue was cut in stripes, dehydrated in isopentane
in liquid nitrogen, and mounted on styropor snips for cryosectioning.
Kidney tissue was sectioned at 15-m thickness. Further procedures
were identical to those as recently described (31). Briefly, sections
were permeabilized (0.3% Triton X-100), blocked for 1 h at room
temperature in blocking solution (2% fetal bovine serum, 2% bovine
serum albumin, 0.2% fish gelatin in phosphate buffered saline), and
incubated with Alexa-conjugated phalloidin (Molecular Probes, Eu-
gene, OR) to visualize F-actin. Specimen were viewed with a confocal
laser scanning microscope (TCS-SP; Leica Microsystems, Heidel-
berg, Germany). To assess F-actin intensity, all images were taken
with identical confocal microscope settings for laser power, photo-
multiplier gain, and pinhole size.
Statistical Analyses
Data are presented as mean SEM. Changes in vascular diameters
and GBF are expressed as percentage changes from the preceding
control values. Paired and unpaired t test, ANOVA, and Bonferroni’s
method for multiple comparisons were used as appropriate to test for
statistical significance. The data have been analyzed both as absolute
and percent values. Values of P  0.05 were considered statistically
significant.
Results
Absolute values for measured parameters in five experimen-
tal groups under control conditions before and after application
of inhibitors are listed in Table 1. MAP was not affected by
local administration of vasoconstrictors or inhibitors in all the
experimental groups, and it remained stable throughout the
experimental protocols if not otherwise indicated.
Effects of ROK and PKC Inhibitors on Basal Vessel
Tone
In the first series of experiments, the effect of increasing
concentrations of the ROK inhibitor Y-27632 (107 to 104
M) on the spontaneous, endogenous tone of the interlobular
artery was determined (Figure 1A). In the interlobular artery,
diameter did not change at 107 and 106 M Y-27632, but it
significantly increased at higher concentrations (105 and 104
M). The vascular pattern of dilation in response to the ROK
inhibitor Y-27632 (104 M) was obtained from the pooled data
of three groups of experiments (Figure 1B). Dilation was
observed preferentially in preglomerular vessels, i.e., in inter-
lobular arteries and in proximal afferent arterioles. Efferent
arterioles also dilated significantly in response to the ROK
inhibitor Y-27632. Y-27632 almost doubled GBF.
The structurally different ROK inhibitor HA-1077 (104 M)
reduced the spontaneous tone in pre- and postglomerular ves-
sels to a similar degree as Y-27632 (Figure 2). However,
dilation of the distal interlobular artery in response to the ROK
inhibitor HA-1077 was somewhat weaker as compared with
Y-27632-induced dilation. Pre- and postglomerular dilation in
response to the PKC inhibitor Ro 31–8220 further revealed the
involvement of PKC in the spontaneous tone of renal vessels
(Figure 2). Although PKC inhibition dilated efferent arterioles
as effectively as the ROK inhibitors, dilation of the distal
interlobular artery in response to the PKC inhibitor was clearly
less.
Effects of ETB Receptor Agonist (IRL 1620), Guanylyl
Cyclase Inhibitor (ODQ), and Adenosine A1 Receptor
Agonist (CPA)
The effects of local application of IRL 1620, ODQ, and CPA
on luminal diameters and on GBF in hydronephrotic rat kid-
neys are depicted in Figure 3. The ETB receptor agonist (IRL
1620) at a local concentration of 108 M constricted both pre-
and postglomerular vessels and decreased GBF. The most
pronounced vasoconstriction was observed in efferent arte-
rioles, in agreement with earlier findings (22). At a local
concentration of 3 · 105 M of the guanylyl cyclase inhibitor
(ODQ), a stable reduction of GBF was reached within 15 min.
The reduction in GBF was due to a rather homogenous vaso-
constriction within the renal arteriolar network ranging from
11% to 19%. The adenosine A1 receptor agonist (105 M
CPA) induced constriction selectively in preglomerular ves-
sels. In accordance with earlier findings (23,24), the strongest
vasoconstriction in response to CPA was observed in the distal
segment of the afferent arteriole in close vicinity to the glo-
merulus. The effects of IRL 1620, ODQ, and CPA were
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completely reversible, with return of hemodynamic parameters
to baseline values after wash out (Table 1).
Effects of ETB Receptor Agonist (IRL 1620) after ROK
and PKC Inhibition
In the presence of the ROK inhibitor Y-27632, the ETB
agonist-induced vasoconstriction was markedly blunted. AsTa
bl
e
1.
A
bs
ol
ut
e
v
al
ue
s
fo
rv
es
se
ld
ia
m
et
er
s,
gl
om
er
ul
ar
bl
oo
d
flo
w
(G
BF
),
an
d
M
A
P
fo
rt
he
di
ffe
re
nt
ex
pe
rim
en
ta
lg
ro
up
s
an
d
fo
rt
he
po
ol
ed
da
ta
o
ft
hr
ee
gr
ou
ps
a
G
ro
up
1
(E
T B
A
go
ni
st)
G
ro
up
2
(E
T B
A
go
ni
st)
G
ro
up
3
(E
T B
A
go
ni
st)
G
ro
up
4
(G
ua
ny
lyl
Cy
cl
as
e
In
hi
bi
to
r)
G
ro
up
5
(A
1
A
go
ni
st)
G
ro
up
s
1,
4,
5
Co
nt
ro
l
A
fte
r
Y
-2
76
32
Co
nt
ro
l
B
ef
or
e
H
A
-1
07
7
A
fte
r
H
A
-1
07
7
Co
nt
ro
l
B
ef
or
e
R
o
31
-8
22
0
A
fte
r
R
o
31
-8
22
0
Co
nt
ro
l
A
fte
r
Y
-2
76
32
Co
nt
ro
l
A
fte
r
Y
-2
76
32
B
ef
or
e
Y
-2
76
32
IL
O
B,
p

m
24
.0

1.
0
30
.0

1.
5
—
—
—
—
—
—
23
.2

1.
3
28
.9

2.
0
25
.2

2.
0
32
.3

2.
3
23
.0

0.
6
IL
O
B,
d

m
13
.1

1.
3
18
.1

1.
3
15
.8

0.
9
15
.8

0.
9
18
.3

0.
9
15
.9

0.
5
15
.8

0.
6
17
.6

0.
6
13
.4

1.
3
17
.9

1.
9
15
.3

1.
5
20
.0

1.
3
13
.9

0.
6
A
FF
,p

m
10
.5

1.
0
14
.2

0.
9
—
—
—
—
—
—
11
.5

0.
5
15
.2

1.
0
12
.2

1.
0
15
.3

1.
4
13
.3

1.
1
A
FF
,d

m
11
.4

0.
7
13
.9

0.
6
—
—
—
—
—
—
10
.6

0.
6
12
.9

0.
8
10
.6

0.
7
13
.1

1.
0
11
.2

0.
6
EF
F

m
12
.6

1.
3
13
.1

1.
3
12
.6

0.
4
12
.3

0.
4
13
.9

0.
4
13
.8

0.
7
12
.8

0.
6
14
.3

0.
6
11
.3

0.
9
12
.1

0.
9
11
.8

1.
4
12
.2

1.
5
11
.1

0.
5
G
BF
n
l/m
in
64

13
66

14
—
—
—
—
—
—
48

5
84

16
44

5
67

18
45

6
M
A
P
m
m
H
g
12
5

1
12
4

1
11
7

2
11
9

3
11
8

3
11
4

4
10
9

4
10
6

3
12
0

2
12
3

4
13
0

4
13
1

3
12
8

3
N
6
6
5
5
5
5
5
5
6
6
7
7
19
a
IL
O
B,
in
te
rlo
bu
la
ra
rt
er
y;
A
FF
,a
ffe
re
nt
ar
te
rio
le
;E
FF
,e
ffe
re
nt
ar
te
rio
le
;p
,p
ro
xi
m
al
;d
,d
ist
al
.D
at
a
ar
e
m
ea
n
s

SE
M
.
Figure 1. Effect of the Rho kinase (ROK) inhibitor Y-27632 on renal
vessels. The ROK inhibitor Y-27632 induced a dose-dependent va-
sodilation in renal vessels. (A) Percent changes of the diameter of the
proximal interlobular artery in response to increasing concentrations
of Y-27632. (B) Percent changes of GBF and of diameters for differ-
ent renal vessels in response to Y-27632 (104 M). ilob, interlobular
artery; aff, afferent arteriole; eff, efferent arteriole; p, proximal; d,
distal. Data are mean  SEM; n  3 (panel A) and n  19 animals
(panel B); * P  0.05.
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shown in Figure 4, the same concentration (108 M) of the
ETB agonist (IRL 1620) as applied in the beginning induced
only small changes in GBF and in vessel diameters (6%; P
0.05) in the presence of the ROK inhibitor Y-27632. A tenfold
higher concentration (107 M) of the ETB agonist (IRL 1620)
was required to obtain a distinct reduction in GBF, whereas
vasoconstriction still remained weak (17%, P  0.05). Im-
portantly, both efferent and preglomerular vasoconstriction in
response to the ETB agonist (IRL 1620) were attenuated by the
ROK inhibitor Y-27632 to a similar extent. The structurally
different ROK inhibitor HA-1077 (104 M) blunted ETB ag-
onist-induced vasoconstriction in pre- and postglomerular ves-
sels to a similar degree as Y-27632 (Figure 5). In contrast, the
PKC inhibitor Ro 31–8220 did not significantly affect ETB
agonist-induced vasoconstriction (Figure 5).
Effects of Guanylyl Cyclase Inhibitor (ODQ) and
Adenosine A1 Receptor Agonist (CPA) after ROK
Inhibition
After ROK inhibition with Y-27632, vasoconstriction in-
duced by the guanylyl cyclase inhibitor (3 · 105 M ODQ) was
completely abolished both in preglomerular vessels and in
efferent arterioles (Figure 6). Likewise, the guanylyl cyclase
inhibitor (ODQ) did not induce a significant reduction of GBF
in the presence of the ROK inhibitor Y-27632.
The same concentration (105 M) of the adenosine A1
agonist (CPA) as applied in the beginning did not alter vessel
diameters in the presence of the ROK inhibitor Y-27632 (Fig-
Figure 2. Effect of ROK versus PKC inhibition on renal vessels.
Percent changes of the diameter of the distal interlobular artery (ilob,
d) and of the efferent arteriole (eff) in response to ROK inhibition
with Y-27632 (104 M) or HA-1077 (104 M) or to PKC inhibition
with Ro 31–8220 (5 · 106 M). Data are mean  SEM; n  14 to 23
vessels of n  5 to 19 animals; * P  0.05 significant diameter
change; o P  0.05 significant difference versus Y-27632; # P  0.05
significant difference versus Y-27632 and HA-1077.
Figure 3. Effect of vasoconstrictors that activate distinct signaling
pathways in renal vessels. Percent changes of glomerular blood flow
(GBF) and vessel diameters in response to the ETB receptor agonist
IRL 1620 (108 M), to the guanylyl cyclase inhibitor ODQ (3 · 105
M), and to the adenosine A1 receptor agonist CPA (105 M). Note the
different vascular patterns of constriction observed in response to the
three different compounds. ilob, interlobular artery; aff, afferent arte-
riole; eff, efferent arteriole; p, proximal; d, distal. Data are mean 
SEM; n  6 to 7 animals; * P  0.05.
Figure 4. Effect of the ROK inhibitor Y-27632 on ETB agonist-
induced renal vasoconstriction. Percent changes of GBF and vessel
diameters in response to the ETB receptor agonist IRL 1620 (108 M)
in the absence and presence of the ROK inhibitor Y-27632 (104 M).
ilob, interlobular artery; aff, afferent arteriole; eff, efferent arteriole; p,
proximal; d, distal. Data are mean SEM; n 6 animals; * P 0.05
significant diameter change; o P 0.05 significant effect of Y-27632.
Figure 5. Effect of ROK versus PKC inhibition on ETB agonist-
induced renal vasoconstriction. Percent changes of the diameter of the
distal interlobular artery (ilob, d) and of the efferent arteriole (eff) in
response to the ETB receptor agonist IRL 1620 (108 M) in the
absence and presence of the ROK inhibitor Y-27632 (104 M) or
HA-1077 (104 M) or the PKC inhibitor Ro 31–8220 (5 · 106 M).
Data are mean  SEM; n  6 to 27 vessels of n  5 to 6 animals; *
P  0.05 significant diameter change; o P  0.05 significant effect of
inhibitor.
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ure 7). Specifically, the marked vasoconstriction located in the
distal afferent arteriole in response to the adenosine A1 agonist
(CPA) under control conditions was completely abolished after
ROK inhibition with Y-27632. However, there was a detect-
able decrease in GBF, indicating possible vasoconstriction
further upstream in larger vessels, e.g., arcuate arteries. A
tenfold higher concentration of the adenosine A1 agonist (104
M CPA) significantly constricted only the proximal interlobu-
lar artery in the presence of the ROK inhibitor Y-27632. At
that high concentration, however, the adenosine A1 agonist
(CPA) evoked systemic effects, i.e., an increase in heart rate
and severe hypotension, being mainly responsible for the large
fall of GBF.
Effects of ROK Inhibition on F-Actin in Renal Vessels
Inhibition of ROK with Y-27632 has been shown to induce
disassembly of stress fibers in cultured cells (11). To test
whether Y-27632 exerted its renal vasodilator effects via
changes in content or structure of filamentous actin in renal
arterioles, Y-27623 treated hydronephrotic kidneys were
stained for F-actin and examined by confocal microscopy.
F-actin intensity and structure did not differ between vessels of
Y-27632-treated and control tissue (Figure 8). Treatment with
the ROK inhibitor Y-27632 affected actin filament structure in
neither vascular smooth muscle cells (arrowheads in Figure 8)
nor endothelial cells (arrows in Figure 8).
Discussion
In the present study, we demonstrate that inhibition of ROK
blunts the constriction related to distinct signaling pathways in
preglomerular vessels as well as in efferent arterioles. The
investigation of the role of ROK in vasoconstriction in vivo
Figure 6. Effect of the ROK inhibitor Y-27632 on renal vasoconstric-
tion induced by guanylyl cyclase inhibition. Percent changes of GBF
and vessel diameters in response to the guanylyl cyclase inhibitor
ODQ (3 · 105 M) in the absence and presence of the ROK inhibitor
Y-27632 (104 M). ilob, interlobular artery; aff, afferent arteriole; eff,
efferent arteriole; p, proximal; d, distal. Data are mean  SEM; n 
6 animals; * P  0.05 significant diameter change; o P  0.05
significant effect of Y-27632.
Figure 7. Effect of the ROK inhibitor Y-27632 on A1 agonist-induced
renal vasoconstriction. Percent changes of GBF and vessel diameters in
response to the adenosine A1 receptor agonist CPA (105 M) in the
absence and presence of the ROK inhibitor Y-27632 (104 M). ilob,
interlobular artery; aff, afferent arteriole; eff, efferent arteriole; p, proxi-
mal; d, distal. Data are mean  SEM; n  7 animals; * P  0.05
significant diameter change; o P  0.05 significant effect of Y-27632.
Figure 8. Effect of the ROK inhibitor Y-27632 on F-actin in renal
vessels. F-actin distribution in arcuate arteries (ARC), interlobular
arteries (ILOB), and afferent arterioles (AFF) of the hydronephrotic
rat kidney visualized by confocal microscopy. Images were taken with
identical settings of confocal parameters for control and tissue treated
with the ROK inhibitor Y-27632 (104 M). Intensity and distribution
of F-actin in renal vessels were similar for control and Y-27632
treated kidneys. Actin filaments around nuclei in smooth muscle cells
are marked by arrowheads; actin filaments in endothelial cells are
marked by arrows. Magnifications: 130 (ARC, Control); 300
(ARC, Y-27632), and 600 (ILOB, AFF).
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became possible with the discovery of specific ROK inhibitors,
i.e., HA-1077 (fasudil) (32) and Y-27632 (11). Y-27632 is the
most selective ROK inhibitor known, and it blocks MLC
kinase only at concentrations above 250 M (11). Using these
two ROK inhibitors it has been shown that inactivation of
MLCP significantly contributes to regulation of vasomotor
tone and blood flow in several tissues and organs (2). However,
the impact of ROK inhibition on the renal vasculature has been
addressed in only one study so far, at a time when the molec-
ular target of HA1077 was unknown (32). Intravenous bolus
injection of HA1077 increased renal blood flow by about 20%
in anesthetized dogs (32).
Endothelin exerts potent renal vasoconstrictor effects in vivo
through activation of ETA and ETB receptors (18,22). Both
ETA and ETB receptors are known to couple to several types of
heterotrimeric G-proteins predominantly leading to PLC acti-
vation and intracellular Ca2 mobilization. ET-1 has been
demonstrated to increase the amount of GTP-RhoA (33) and to
induce most effective phosphorylation of MLC and contraction
in bovine aortic VSMC (9). Specifically, the ETB receptor is
able to couple to G12/13, which in turn activates RhoA (34).
Our results demonstrate an important role of ROK in mediating
ETB-induced renal vasoconstriction. ETB receptor stimulation
leads to marked efferent arteriolar constriction, which is
blocked by Y-27632 or HA-1077; therefore, ROK-mediated
constriction is clearly operative in efferent arterioles. In agree-
ment with our findings, inhibition of the Rho/ROK pathway
blunted ET-1-induced vasoconstriction in mammary, mesen-
teric, penile, cerebral, and coronary arteries (8,35–38). Pre-
venting coronary artery vasospasm in response to ET-1, ROK
inhibition protected against myocardial ischemia in rabbits
(13,39).
The PKC inhibitor Ro 31–8220 dilated pre- and postglo-
merular vessels, being equally effective as ROK inhibitors in
the efferent arteriole but less effective in the interlobular artery
(Figure 2). Thus, part of the basal tone in vessels of the
hydronephrotic kidney in vivo is due to activation of PKC.
Despite the reduction of basal vessel tone, PKC inhibition with
Ro 31–8220 failed to prevent ETB-induced vasoconstriction in
our experiments. The ability of PKC to induce constriction of
afferent and efferent arterioles has been demonstrated by stim-
ulating PKC with phorbol ester and a diacylglycerol analogue
(40). However, selective inhibitors of PKC did not affect
norepinephrine- and 20-HETE-induced constriction of isolated
interlobar and interlobular arteries, respectively (41,42), sug-
gesting limited or selective activation of PKC by vasoconstric-
tors. Furthermore, the inability of Ro 31–8220 to inhibit ETB-
induced vasoconstriction clearly demonstrates that the effects
of ROK inhibitors Y-27632 and HA-1077 occurred indepen-
dently of the PKC pathway.
The adenosine A1 receptor decreases intracellular cAMP
levels through Gi protein coupling and has a unique function in
the kidney in that it mediates the tubuloglomerular feedback
(43). Consistent with this notion, the adenosine A1 receptor
agonist CPA induced marked vasoconstriction in the distal
segment of the afferent arteriole, which was sensitive to ROK
inhibition in the present study. Besides cAMP, the cyclic
nucleotide cGMP importantly regulates renal vessel tone being
the second messenger of natriuretic peptides and NO (44).
Inhibition of soluble guanylyl cyclase by ODQ induced a
strong vasoconstriction of preglomerular vessels and efferent
arterioles in our present study, comparable to the effects of NO
synthesis blockade by L-NAME (45). Likewise, Trottier et al.
(46) reported that ODQ completely inhibits the renal vasodi-
lation evoked by endogenous NO. Similar to the effect of ROK
inhibition on vasoconstriction elicited by reduced cAMP lev-
els, Y-27632 blocked renal vasoconstriction when cGMP lev-
els were lowered by ODQ.
There are several targets in the pathways of agonist-induced
MLC phosphorylation that can be inhibited by cAMP- and
cGMP-dependent kinases (2,3). Thus, changes in intracellular
cAMP and cGMP levels result in more or less pronounced
changes of vasomotor tone depending on the current degree of
MLC phophorylation. Our observation that decreasing cAMP
or cGMP levels failed to induce vasoconstriction in the pres-
ence of the ROK inhibitor Y-27632 could be interpreted in a
way that both nucleotides interfere with the Rho/ROK path-
way. Indeed it has been shown that both cAMP- and cGMP-
dependent kinases inhibit the Rho/ROK pathway via serine
phosphorylation of RhoA (47–49). On the other hand, in our
study ROK inhibition could have lowered the level of MLC
phosphorylation to such an extent that reduction of cAMP or
cGMP was no longer able to induce vasoconstriction through
disinhibition of pathways unrelated to the Rho/ROK pathway.
In any case, our results indicate that ROK inhibition impairs
vasoconstriction mediated by cAMP and cGMP pathways.
Besides MLCP, ROK also inactivates LIM kinase, thereby
inhibiting actin depolymerization (16). Consequently, ROK
inhibition has been shown to consistently cause disassembly of
stress fibers and a decrease of the F- to G-actin ratio in various
cultured cell types, including VSMC (11,50). Matrougui et al.
(17) demonstrated that ROK inhibition as well as actin filament
disruption by cytochalasin B abolished the contractile response
of isolated mesenteric arteries to angiotensin II. For the first
time, our experiments provide evidence that ROK inhibition
results in vasodilation without affecting F-actin organization in
vessels in vivo. Additional downstream effectors of RhoA (e.g.,
mDia) (16), which stimulate actin polymerization, might be
responsible for the maintenance of the actin cytoskeleton in
VSMC during ROK inhibition in vivo.
In their first report on Y-27632, Uehata et al. (11) have
already described that ROK inhibition induces stronger reduc-
tions in arterial BP in hypertensive as compared with normo-
tensive rats. Recently, this finding has been extended to hu-
mans, in that the increase in forearm blood flow induced by the
ROK inhibitor HA-1077 was about twofold higher in hyper-
tensive patients as compared with normotensive subjects (12).
There are two findings suggesting a potential therapeutic ben-
efit of ROK inhibition in the renal vasculature. First, lovastatin
reduces the level of Rho proteins in renal vessels of hyperten-
sive rats (51). Second, enhanced activation of phospholipase D
by angiotensin II in renal VSMC of hypertensive rats is sen-
sitive to blockade of the Rho/ROK pathway (52). The fact that
ROK inhibition blunted vasoconstriction in preglomerular ves-
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sels as well as in efferent arterioles is of therapeutic relevance
and contrasts with the action of Ca2 antagonists, which are
without effect on L-type channel-lacking efferent arterioles
(53,54).
In conclusion, we demonstrate that ROK inhibitors blunt
renal vasoconstriction evoked by distinct signaling pathways
without affecting vascular F-actin organization in vivo.
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